ArticleAnnals of translational medicine2022

The feasibility, safety, and efficacy of Paxlovid treatment in SARS-CoV-2-infected children aged 6-14 years: a cohort study.

Gangfeng Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.